Vitamin D Deficiency Diagnosis and Treatment

Diagnostic Considerations

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, causes vitamin D malabsorption through intestinal inflammation, reduced absorptive surface area, and altered bile acid metabolism 1
Post-bariatric surgery, particularly malabsorptive procedures like Roux-en-Y gastric bypass, dramatically reduces vitamin D absorption and requires intramuscular administration or substantially higher oral doses (4,000-5,000 IU daily) 1
Short bowel syndrome reduces available intestinal surface area for vitamin D absorption 1
Pancreatic insufficiency impairs fat digestion necessary for vitamin D₃ absorption 1
Celiac disease (untreated) causes malabsorption requiring modified supplementation approaches 1
X-Linked Hypophosphatemia (XLH) can present with low vitamin D levels alongside hypophosphatemia, elevated FGF23, and normal or low-normal calcium 2
XLH is distinguished by primary phosphate wasting rather than calcium/vitamin D metabolism defects 2
Requires treatment with active vitamin D (calcitriol 20-30 ng/kg daily or alfacalcidol 30-50 ng/kg daily) plus phosphate supplements, not standard cholecalciferol 2

Serum 25(OH)D is the definitive test for vitamin D status, with severe deficiency defined as <10-12 ng/mL 1, 3
Serum calcium should be measured to rule out hypocalcemia and establish baseline before supplementation 1
Serum PTH helps distinguish primary vitamin D deficiency (elevated PTH) from hereditary disorders; levels >300 pg/mL despite vitamin D repletion suggest need for active vitamin D analogs 1
Serum phosphorus is typically normal or low in nutritional deficiency but characteristically low in XLH 2

Loading phase: Cholecalciferol (D3) 50,000 IU weekly for 8-12 weeks is preferred over ergocalciferol (D2) due to superior bioavailability and longer maintenance of serum levels 1, 3
Severe deficiency (<10 ng/mL): Consider 50,000 IU weekly for 12 weeks, or for symptomatic patients with high fracture risk, 8,000 IU daily for 4 weeks then 4,000 IU daily for 2 months 1
Maintenance: Transition to 1,500-2,000 IU daily or 50,000 IU monthly after loading 1, 3
Target level: Achieve ≥30 ng/mL for anti-fracture efficacy 1, 3
Intramuscular vitamin D3 50,000 IU is the preferred route when available, resulting in significantly higher 25(OH)D levels and lower rates of persistent deficiency compared to oral supplementation 1
When IM unavailable: Use substantially higher oral doses of 4,000-5,000 IU daily for 2 months 1
Post-bariatric surgery: Require at least 2,000 IU daily maintenance to prevent recurrent deficiency 1

Never use active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) to treat nutritional vitamin D deficiency, as they bypass normal regulatory mechanisms, do not correct 25(OH)D levels, and carry higher risk of hypercalcemia 1, 3
Avoid single ultra-high doses (>300,000 IU) as they may be inefficient or potentially harmful 1
Ensure adequate calcium intake of 1,000-1,500 mg daily from diet plus supplements, as calcium is necessary for clinical response to vitamin D therapy 1, 3
Monitor for hypercalcemia by checking serum calcium and phosphorus at least every 3 months during treatment; discontinue all vitamin D if corrected calcium exceeds 10.2 mg/dL 1
Recheck 25(OH)D levels at 3 months after initiating treatment to confirm adequate response, as individual responses vary due to genetic differences in vitamin D metabolism 1, 3